<?xml version="1.0"?><rss version="2.0"><channel><title>RxBriefing</title><link>https://rxbriefing.com</link><description>Pharma, biotech, medtech and health AI stock news</description><item><title>As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university</title><link>https://www.statnews.com/2026/10/14/american-science-funding-university-industry-shift-stat-summit-boston-2026/?utm_campaign=rss</link><guid>d246a164bb8e</guid><pubDate>Wed, 14 Oct 2026 22:13:33 +0000</pubDate><description>White House planned shift of research funding from universities to industry risks creating a drought in basic research, science leaders say</description></item><item><title>FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash</title><link>https://www.fiercepharma.com/pharma/fda-clears-immunitybio-anktiva-expansion-bladder-cancer-after-regulatory-whiplash</link><guid>ff26572e99f6</guid><pubDate>Wed, 14 Oct 2026 21:30:24 +0000</pubDate><description>To expand Anktiva’s label, the FDA adopted a new approach to how it evaluates treatments for BCG-unresponsive NMIBC. The new regulatory path essentially allowed ImmunityBio to bypass an expensive phase 3 trial that competitor Johnson &amp;…</description></item><item><title>Big-ticket hospital deals are becoming the M&amp;A story of 2026</title><link>https://www.fiercehealthcare.com/providers/big-ticket-hospital-deals-are-becoming-ma-story-2026</link><guid>947d9e057d0e</guid><pubDate>Wed, 14 Oct 2026 21:15:20 +0000</pubDate><description>For a third consecutive quarter, the hospital industry has hosted multiple new transactions in which the smaller party&#x27;s annual revenue exceeds $1 billion, per Kaufman Hall&#x27;s quarterly report. The news comes alongside signs of worsening…</description></item><item><title>Eli Lilly (LLY) Stock Looks Undervalued As Its 404% Run Continues</title><link>https://finnhub.io/api/news?id=c5720f7edbb8924ddf3b82b1e6c622459a54a95d702757ea135323e710152bf6</link><guid>e43997063e1c</guid><pubDate>Wed, 14 Oct 2026 21:11:03 +0000</pubDate><description>Eli Lilly’s stock has become one of the most closely watched pharmaceuticals on the market, and at around US$1,166 per share the question for investors is whether that price is fully supported by the cash flows the business can generate…</description></item><item><title>Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin</title><link>https://finnhub.io/api/news?id=cdd4ce3b33fa5fdc6d3866d2bda3d93869e7bbb137ac24183cb3cba5411619bc</link><guid>508affc659c8</guid><pubDate>Wed, 14 Oct 2026 21:10:00 +0000</pubDate><description>SAN DIEGO, October 14, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of…</description></item><item><title>Dow Jones Futures: Dell, AMD, CoreWeave Lead Market Sell-Off On AI Fears; Taiwan Semiconductor Due</title><link>https://finnhub.io/api/news?id=e1a55a659c9fcf8681b74636abc17536f30cfc993dedc919509f215b84e95fb8</link><guid>9fa193b4ec06</guid><pubDate>Wed, 14 Oct 2026 21:09:25 +0000</pubDate><description>The stock market tested key levels on Fed and AI fears. Dell, AMD, CoreWeave were big losers. Taiwan Semiconductor earnings loom.</description></item><item><title>Walmart to expand health benefits for employees, including $0 prescriptions, rare disease care</title><link>https://www.fiercehealthcare.com/retail/walmart-expand-health-benefits-employees-including-over-250-zero-dollar-prescriptions</link><guid>e6f2d6382305</guid><pubDate>Wed, 14 Oct 2026 21:00:33 +0000</pubDate><description>The new offerings include “zero cost” prescriptions, expanded Centers of Excellence for rare conditions and paid NICU leave.</description></item><item><title>Ultragenyx makes swift $413M return on FDA review vouchers after summer of gene therapy nods</title><link>https://www.fiercepharma.com/pharma/ultragenyx-makes-swift-413m-return-fda-review-vouchers-after-summer-gene-therapy-nods</link><guid>3efcab701e25</guid><pubDate>Wed, 14 Oct 2026 21:00:33 +0000</pubDate><description>Hot off a pair of key FDA approvals this summer, rare disease specialist Ultragenyx has wasted little time cashing in on the priority review vouchers it earned from the green lights.</description></item><item><title>What Could BSX Stock Be Worth In Three Years?</title><link>https://finnhub.io/api/news?id=ef7c7029bef1f6c640c65a25788aafde6dcff4633ad4476372e4ff68562445ff</link><guid>a88ed479f6bf</guid><pubDate>Wed, 14 Oct 2026 20:55:29 +0000</pubDate><description>Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends, excluding readings above a hundred. Investors evaluating the stock must look ahead to…</description></item><item><title>Pfizer (PFE) Gains As Market Dips: What You Should Know</title><link>https://finnhub.io/api/news?id=30968c24443e8adac169e6499d5170bb4ec0b066c47f0edd1601090ab47ea410</link><guid>743151885126</guid><pubDate>Wed, 14 Oct 2026 20:45:05 +0000</pubDate><description>The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close.</description></item><item><title>Hims &amp; Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights</title><link>https://finnhub.io/api/news?id=94675cabb6e4346a3fa3be5d060829c2b7fa76a85f058ac24bb25c68c747e525</link><guid>7cd1555734f7</guid><pubDate>Wed, 14 Oct 2026 20:45:02 +0000</pubDate><description>In the closing of the recent trading day, Hims &amp; Hers Health, Inc. (HIMS) stood at $27.72, denoting a -6.7% move from the preceding trading day.</description></item><item><title>Zodoc acquires health tech company Sohar Health for automated benefits eligibility checks</title><link>https://www.fiercehealthcare.com/ai-and-machine-learning/zodoc-acquires-health-tech-company-sohar-health-automated-benefits</link><guid>90e2b6fa6354</guid><pubDate>Wed, 14 Oct 2026 20:30:26 +0000</pubDate><description>Zocdoc acquired insurance technology company Sohar Health as it pushes to evolve beyond an appointment-booking marketplace into broader healthcare access infrastructure.</description></item><item><title>Waystar to Report Third Quarter 2026 Financial Results on November 2, 2026</title><link>https://www.prnewswire.com/news-releases/waystar-to-report-third-quarter-2026-financial-results-on-november-2-2026-302908884.html</link><guid>d3ba20804151</guid><pubDate>Wed, 14 Oct 2026 20:30:00 +0000</pubDate><description>LEHI, Utah and LOUISVILLE, Ky., Oct. 14, 2026 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced it will report financial results for the third quarter ended September…</description></item><item><title>Top Research Reports for Mastercard, AstraZeneca &amp; Sandisk</title><link>https://finnhub.io/api/news?id=e77819e15691740e97514316cc464ea955586b2feffc939bf5735ff9937d8bf1</link><guid>d34cbea2b125</guid><pubDate>Wed, 14 Oct 2026 20:28:00 +0000</pubDate><description>Mastercard&#x27;s payment growth, AstraZeneca&#x27;s drug pipeline and Sandisk&#x27;s AI-driven SSD demand headline today&#x27;s top research reports, revealing key growth drivers and risks for investors.</description></item><item><title>STAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseas</title><link>https://www.statnews.com/pharmalot/2026/10/14/trump-administration-delays-new-rule-that-could-restrict-imported-meds-from-canad-and-overseas/?utm_campaign=rss</link><guid>c36bd417c56e</guid><pubDate>Wed, 14 Oct 2026 20:16:59 +0000</pubDate><description>The Trump administration is delaying by 90 days a federal rule that could prevent Americans from obtaining prescription drugs from licensed international pharmacies.</description></item><item><title>Centene unveils national provider gold card program</title><link>https://www.fiercehealthcare.com/payers/centene-unveils-national-provider-gold-card-program</link><guid>a39e0c716944</guid><pubDate>Wed, 14 Oct 2026 20:15:20 +0000</pubDate><description>Centene is aiming to simplify the prior authorization process with the launch of a new nationwide gold card program.</description></item><item><title>Teladoc Health to Announce Third Quarter 2026 Financial Results</title><link>https://www.globenewswire.com/news-release/2026/10/14/3381136/0/en/teladoc-health-to-announce-third-quarter-2026-financial-results.html</link><guid>988a31d0f1bd</guid><pubDate>Wed, 14 Oct 2026 20:05:00 +0000</pubDate><description>NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2026 results on Wednesday, October 28, 2026, after the market closes. In…</description></item><item><title>Veeva to Host Virtual Investor Day on November 5, 2026</title><link>https://www.prnewswire.com/news-releases/veeva-to-host-virtual-investor-day-on-november-5-2026-302907886.html</link><guid>6b2399cf6d1b</guid><pubDate>Wed, 14 Oct 2026 20:05:00 +0000</pubDate><description>PLEASANTON, Calif., Oct. 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026. The event will begin at 1:30 p.m. PT and will conclude at approximately 3:30 p.m. PT. Veeva…</description></item><item><title>Veeva to Host Virtual Investor Day on November 5, 2026</title><link>https://finnhub.io/api/news?id=0bc2dcbb4fcf2a6fb9c7c3152afb3f75f6dccc8855401e1cae088588608b1219</link><guid>e909896ca221</guid><pubDate>Wed, 14 Oct 2026 20:05:00 +0000</pubDate><description>Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 5, 2026. The event will begin at 1:30 p.m. PT and will conclude at approximately 3:30 p.m. PT.</description></item><item><title>Sector Update: Healthcare Stocks Gain Late Afternoon</title><link>https://finnhub.io/api/news?id=cbabb8ef212ab4222c551a8ad2ecafca2aea27ba99cf952f6f719ae2b9f7afda</link><guid>8d3d7487730b</guid><pubDate>Wed, 14 Oct 2026 19:56:15 +0000</pubDate><description>Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State</description></item><item><title>Trump administration boots 189K deceased, duplicate enrollees off ACA subsidies</title><link>https://www.healthcaredive.com/news/trump-administration-boots-189k-deceased-duplicate-enrollees-off-aca-subsi/833037/</link><guid>87fa08dee05e</guid><pubDate>Wed, 14 Oct 2026 19:40:27 +0000</pubDate><description>It comes amid a broader crackdown on the ACA exchanges as the Trump administration continues its efforts to identify “fraud, waste and abuse” in federal programs.</description></item><item><title>Trump administration boots 189,000 deceased, duplicate enrollees off ACA subsidies</title><link>https://www.healthcaredive.com/news/trump-administration-boots-189000-deceased-duplicate-enrollees-off-aca-su/833037/</link><guid>66eac81162ed</guid><pubDate>Wed, 14 Oct 2026 19:40:27 +0000</pubDate><description>It comes amid a broader crackdown on the ACA exchanges as the Trump administration continues its efforts to identify “fraud, waste and abuse” in federal programs.</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. General Mills</title><link>https://finnhub.io/api/news?id=b8ee77232da86a78183d15a5616a6bb21a5c2408239f1e2c7c4926f0acf76a2b</link><guid>eb8aa06b10fb</guid><pubDate>Wed, 14 Oct 2026 19:34:38 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and General Mills 7.</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. British American Tobacco</title><link>https://finnhub.io/api/news?id=3ff6d0ac3a491df2b4d918d8a2cc2eb3868a4183edc6b5ff9bf6b746e25d83e2</link><guid>84ef5c847a74</guid><pubDate>Wed, 14 Oct 2026 19:25:19 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and British American Tobacco 6.</description></item><item><title>Is Veeva Systems (VEEV) Quietly Redefining Clinical Tech Moats With IQVIA Deal And Basics Uptake?</title><link>https://finnhub.io/api/news?id=29ff31fbaae98425de98a304f7b39be50a0d40b6b8103486c6d16bf0d85652d2</link><guid>f32b5858bbf7</guid><pubDate>Wed, 14 Oct 2026 19:17:18 +0000</pubDate><description>In recent days, IQVIA announced it has selected Veeva Systems’ CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard applications across its clinical development studies, extending their earlier EDC partnership and making…</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. UPS</title><link>https://finnhub.io/api/news?id=6749c3c62359b0a0c47f0efb52a4867735713390da08de110f47958dedfd4031</link><guid>8039e0afce3e</guid><pubDate>Wed, 14 Oct 2026 19:12:58 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and UPS yields 7.</description></item><item><title>Discover which dow jones stocks are making waves on Wednesday.</title><link>https://finnhub.io/api/news?id=0da62e5b5741f2c815f6c9d71ebb7308149769088a6488e233b3825b4510e5a1</link><guid>af5661a2f572</guid><pubDate>Wed, 14 Oct 2026 19:10:15 +0000</pubDate><description>Uncover the latest developments among dow jones stocks in today&#x27;s session. Stay tuned to the dow jones index&#x27;s top gainers and losers on Wednesday.</description></item><item><title>Top S&amp;P500 movers in Wednesday&#x27;s session</title><link>https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f</link><guid>2ff1b99cff80</guid><pubDate>Wed, 14 Oct 2026 19:05:01 +0000</pubDate><description>Wondering what&#x27;s happening in today&#x27;s session for the S&amp;P500 index? Stay informed with the top movers within the S&amp;P500 index on Wednesday.</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. Healthpeak</title><link>https://finnhub.io/api/news?id=6e5fdea3ffe327c06c850de8344a8d4d33f2aaa210032832eb68a935e64746d3</link><guid>a6f995e45e59</guid><pubDate>Wed, 14 Oct 2026 19:01:58 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and Healthpeak Properties yields 6.</description></item><item><title>Johnson &amp; Johnson CFO taps internal investment for medtech growth</title><link>https://finnhub.io/api/news?id=480d3682d7e458c274910231e3e67e274873fe877a2a7d687179a782e8bae3e2</link><guid>bcc06ff5674b</guid><pubDate>Wed, 14 Oct 2026 18:43:59 +0000</pubDate><description>The pharma company is on track to reach $100 billion in recorded revenue despite “temporary” headwinds in its medtech segment, executives said.</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. Edison International</title><link>https://finnhub.io/api/news?id=82a75823e061cb1369148e13a89f3b32292e704c410751ce5d0249849e48e8f1</link><guid>bc7806260216</guid><pubDate>Wed, 14 Oct 2026 18:40:45 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and Edison International yields 6.</description></item><item><title>Better High-Yield Dividend Stock: Pfizer vs. Clorox</title><link>https://finnhub.io/api/news?id=adfe62979ba6dfea2ebdafc51506ca7bf6a011ab0d0ccd3f59e0d7f2ea04b9bf</link><guid>ae1f6e4a4e81</guid><pubDate>Wed, 14 Oct 2026 18:34:28 +0000</pubDate><description>Key TakeawaysPfizer yields 6. 3% and Clorox yields 6.</description></item><item><title>How consumer tech company Whoop is building for Medicare patients</title><link>https://www.statnews.com/2026/10/14/whoop-ami-bhatt-population-health-stat-summit-boston-2026/?utm_campaign=rss</link><guid>e0f1d38f2981</guid><pubDate>Wed, 14 Oct 2026 18:16:08 +0000</pubDate><description>Whoop&#x27;s chief medical officer, said the company&#x27;s work with Medicare is an opportunity to prove its ability to improve health at the population level.</description></item><item><title>Fierce Healthcare Layoff Tracker—Montrose Regional shutters 77 roles; 73 cuts at City of Hope</title><link>https://www.fiercehealthcare.com/finance/fierce-healthcare-layoff-tracker-2026-job-cuts-eliminations-health-systems-hospitals</link><guid>a82e320024fb</guid><pubDate>Wed, 14 Oct 2026 18:15:22 +0000</pubDate><description>Stick with this tracker for the latest layoff and workforce updates from across healthcare.</description></item><item><title>IQVIA, Veeva expand on existing partnership for speedier clinical trials</title><link>https://www.fiercebiotech.com/cro/iqvia-veeva-expand-partnership-speedy-clinical-trials</link><guid>5491076087d9</guid><pubDate>Wed, 14 Oct 2026 18:15:21 +0000</pubDate><description>Clinical research giant IQVIA and cloud system provider Veeva Systems have expanded their partnership to further increase trial speed and efficiency.</description></item><item><title>Veeva Systems (VEEV) Becomes Default Clinical Software Across A Major Research Partner</title><link>https://finnhub.io/api/news?id=f452f715d7e0f1bc97a8443ccdd5a976c38cc88ead2944ae60a179f6ffc70a2a</link><guid>e0a7f47f477d</guid><pubDate>Wed, 14 Oct 2026 18:15:06 +0000</pubDate><description>Veeva Systems (NYSE:VEEV) said IQVIA will adopt Veeva&#x27;s core clinical applications as enterprise standards across all IQVIA studies. The expanded agreement covers Veeva Clinical Trial Management System, eTMF, Study Startup, and Site…</description></item><item><title>Most active S&amp;P500 stocks in Wednesday&#x27;s session</title><link>https://finnhub.io/api/news?id=4a188658206b81a14d2781a8560ffb791badea88fc7af0c4f67ced56d4798879</link><guid>94bf1d5f6a08</guid><pubDate>Wed, 14 Oct 2026 18:05:02 +0000</pubDate><description>Looking for the most active S&amp;P500 stocks in today&#x27;s session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.</description></item><item><title>Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow</title><link>https://finnhub.io/api/news?id=f670d1d74e37f08a6d8be16188262f2249ccce4c38fd2a3cf3d73eab4f7f1ae9</link><guid>21b4ff99d305</guid><pubDate>Wed, 14 Oct 2026 18:01:31 +0000</pubDate><description>2026-10-14. The following slide deck was published by Arrowhead Pharmaceuticals, Inc.</description></item><item><title>CMS takes aim at duplicative ACA, Medicaid enrollments</title><link>https://www.fiercehealthcare.com/regulatory/cms-takes-aim-duplicative-aca-medicaid-enrollments</link><guid>b99a7e70077c</guid><pubDate>Wed, 14 Oct 2026 18:00:28 +0000</pubDate><description>The Trump administration has put a focus on rooting out fraud, waste and abuse, and on Wednesday, regulators offered a look at progress to date in those efforts.</description></item><item><title>Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancer</title><link>https://www.fiercebiotech.com/research/merck-backed-ionctura-touts-pi3k-delta-inhibitor-metastatic-eye-cancer</link><guid>15b65869cc3f</guid><pubDate>Wed, 14 Oct 2026 18:00:27 +0000</pubDate><description>iOnctura’s PI3K delta inhibitor shows promise in phase 1 study in patients with mostly pre-treated metastatic melanoma.</description></item><item><title>Johnson &amp; Johnson: Stop Paying A Premium For Disappointment - Strong Sell</title><link>https://finnhub.io/api/news?id=7cc8cebe36a96844c7171a8bfe00ab71c7475d484ecd225cd55276f0950d1c5c</link><guid>c426a0b8b894</guid><pubDate>Wed, 14 Oct 2026 17:54:49 +0000</pubDate><description>JNJ Q3 2026 earnings look strong, but deeper analysis shows declining shareholder earnings. Click for more on JNJ stock.</description></item><item><title>Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update</title><link>https://finnhub.io/api/news?id=b6275f90ccaed1d768e7b9b0b6759e778d3a83e60dd01e9ef842c1700e2c259f</link><guid>5114f3df5923</guid><pubDate>Wed, 14 Oct 2026 17:50:00 +0000</pubDate><description>BOSTON, October 14, 2026--Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update</description></item><item><title>WCG unveils AI-powered solution to accelerate clinical trial kickoffs</title><link>https://www.fiercebiotech.com/cro/wcg-announces-ai-powered-solution-accelerate-clinical-trial-start</link><guid>938bfd3e8f5b</guid><pubDate>Wed, 14 Oct 2026 17:45:22 +0000</pubDate><description>WCG, a clinical trials solutions provider, is launching an AI-powered program dubbed Activation Intelligence to help study sites accelerate clinical trial start-up.</description></item><item><title>Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide</title><link>https://finnhub.io/api/news?id=bba9e704787248022ab3a825a38de7555bdc9574246e03fa902039829411d491</link><guid>cf0d847668b1</guid><pubDate>Wed, 14 Oct 2026 17:39:00 +0000</pubDate><description>Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&amp;P 500 fell 1.10% on the day and 1.18% for the week, while the Russell 2000 tumbled 1.70% and now carries an…</description></item><item><title>Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.</title><link>https://finnhub.io/api/news?id=19b85bc72b748e5c4f9df4d280603355fd2cbda4b56f2bfe016353e892bc2ed5</link><guid>6919a5da37e4</guid><pubDate>Wed, 14 Oct 2026 17:33:00 +0000</pubDate><description>Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level since August.</description></item><item><title>Stocks making big moves yesterday: Bumble, Kontoor Brands, UnitedHealth, SentinelOne, and Flex</title><link>https://finnhub.io/api/news?id=c7cc264862bc8ed7a078fab091430aeca72103375a1dce1f659c00990bd096f2</link><guid>fad25947031a</guid><pubDate>Wed, 14 Oct 2026 17:24:07 +0000</pubDate><description>Check out the companies making headlines yesterday:</description></item><item><title>Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig</title><link>https://finnhub.io/api/news?id=d8d9b22cb29f080cb5db8434b1c01f2ee57596e9baf41fa5ccfc107115e9db22</link><guid>b12f8dbbf836</guid><pubDate>Wed, 14 Oct 2026 17:22:00 +0000</pubDate><description>Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that the first patient has been dosed in the clinical study of spevatamig for the…</description></item><item><title>Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial</title><link>https://finnhub.io/api/news?id=140171bc124083f8c972d11e9a2e980287208002c9d126fdf033731f2c953fcb</link><guid>bedf23bf1c01</guid><pubDate>Wed, 14 Oct 2026 17:21:04 +0000</pubDate><description>Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients.</description></item><item><title>Readily secures $11M series A to continue building out AI regulatory compliance platform</title><link>https://www.fiercehealthcare.com/finance/readily-secures-11m-series-continue-building-out-ai-regulatory-compliance-platform</link><guid>c1e09d0e22a5</guid><pubDate>Wed, 14 Oct 2026 17:15:21 +0000</pubDate><description>Artificial intelligence compliance platform Readily raised $11 million in series A funding to support development of its enterprise oversight platform.</description></item><item><title>These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?</title><link>https://finnhub.io/api/news?id=a6a4f6f24c866e68c6cde594f797d5868f29abd7851bb0d3528f7a171b7a2d54</link><guid>d3afcbc52b42</guid><pubDate>Wed, 14 Oct 2026 17:15:06 +0000</pubDate><description>Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth buying right now.</description></item></channel></rss>